Menu
Search Close

Investors

Share Information

Other exchanges or trading platforms where Scancell Holdings plc securities are admitted or traded:

Scancell Holdings securities are listed on AIM

The number of securities in issue:

The company has an issued share capital of 312,058,098 ordinary shares of 0.1p each, all of which are called up and fully paid.

Pursuant to the License and Supply Agreement (‘the Agreement’) dated 13 July 2009, the Company has granted options over 6,369,250 ordinary shares to ICHOR at 4.5p per share.

Directors’ Share Options:

The Company has granted the following options to Directors of the Company. 

Option holder

Option price per ordinary share

Number of ordinary shares under option

Last day of exercise period

John Chiplin

17.0p

3,000,000

18th April 2026

 Lindy Durrant

4.5p

3,850,000

14th July 2020

Lindy Durrant

33.2p

3,500,000

31st December 2023

Richard  Goodfellow

4.5p

2,880,000

14th July 2020

Richard  Goodfellow

33.2p

3,500,000

31st December 2023

Sally Adams

30.5p

500,000

18th June 2024

 

In addition to the above, the Company has granted options over 3,662,960 shares of the Company to various other persons at exercise prices between 2.5p and 33.2p.

Percentage of AIM securities not in public hands:

As at 19th May 2017 the percentage of AIM securities not in public hands was: 21.72%

Restrictions on the transfer of securities:

There are no restrictions on the transfer of shares.

Identity and percentage holdings of significant shareholders:

As at 19th May 2017 the identity and percentage holdings of significant shareholders were: 

 

Ordinary shares at 0.1p each

 

 Number

 Percentage

 Reyker Nominees Limited   

49,422,927

15.84%

 Share Nominees Limited

28,675,439

 9.19%

Hargreaves Lansdown Nominees Limited

24,873,539

7.97%

Scancell Holdings plc directors and related holdings

18,363,875

5.88%

Barclayshare Nominees Limited

18,101,969

5.80%

Nortrust Nominees Limited

16,000,000

5.13%

The Bank of New York Nominees

13,000,000

4.17%

Huntress CI Nominees Limited

11,309.220

3.62%

Lynchwood Nominees Limited

10,968,979

3.52%

Scientific Papers

PIVAC-15 

PIVAC-15 Programme


PIVAC SCIB2 Poster

Wei Xue, Rachael Metheringham, Victoria Brentville, Katherine Cook, Peter Symonds, Ian Daniel and Lindy Durrant


PIVAC SCIB1 resected disease

L.G. Durrant, C.Ottensmeier, C. Mulatero, P.Lorigan, R.Plummer, R.Metheringham, V.Brentville, L.Machado, I.Daniels, D.Hannaman & P.M.Patel


PIVAC SCIB1 plus checkpoint inhibition 

Wei Xue, Victoria Brentville, Rachael Metheringham, Katherine Cook, Peter, Symonds, Ian Daniel, and Lindy Durrant


PIVAC Moditope poster 2

V.Brentville, W.Xue, P.Symonds, K.Cook, B.Gunn, R.Metheringham and L.G. Durrant


PIVAC Moditope poster 1

Katherine Cook, Ian Daniels, Victoria Brentville, Rachael Metheringham, Wei Xue, Peter Symonds, Tracy Pitt, Mohamed Gijon and Lindy Durrant


Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4 T-Cell–Mediated Antitumor Immunity

Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Katherine Cook, Wei Xue, and Lindy G. Durrant


ASCO Poster June 2015

P.M Patel, C Ottensmeier, C Mulatero, P Lorigan, R Plummer, M Cunnell, R Metheringham, V Brentville, L Machado, I Daniels, D Hannaman, L.G Durrant


AACR Moditope® poster April 2015 

Victoria A Brentville, Rachael L Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Wei Xue, Lindy G Durrant


High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
Victoria A. Brentville, Rachael L. Metheringham, Barbara Gun and Lindy G. Durrant


Using monoclonal antibodies to stimulate antitumour cellular immunity
Lindy Durrant, Victoria Pudney and Ian Spendlove

ASCO poster June 2014
P.M Patel, L.G Durrant, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, M. Cunnell, R. Metheringham, V. Brentville, L. Machado, I. Daniels and D. Hannaman


Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses
Lindy Durrant, Victoria Pudney, Ian Spendlove and Rachel Metheringham


DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8 T cells
Victoria A. Pudney, Rachael L. Metheringham, Barbara Gunn, Ian Spendlove, Judith M. Ramage and Lindy G. Durrant


Antibodies designed as effective cancer vaccines
R.L. Metheringham, V.A. Pudney, B. Gunn, M. Towey, I. Spendlove and L.G. Durrant


Webcasts, Interviews and Media Coverage

Scancell raises £5mln in 'most successful round they've ever had' - CEO Richard Goodfellow

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP) talks through with Proactive Investors their £5mln raise to fund clinical work on their pipeline of cancer immune-therapies.

Fri, 12 May 2017 07:57:00

Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.

Wed, 01 Feb 2017 09:53:00

Scancell poised for “significant” year with its immuno-oncology portfolio

"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

Tue, 11 Jul 2017 12:30:00